4.4 /5

TIGIT as an Emerging Clinical Target

24 Sep 2020

About Followers Reviews Exhibitors Photos Speakers

TIGIT as an Emerging Clinical Target - UPMC Hillman Cancer Center, Merck, Stanford University, MD Anderson Cancer Center and more!. Keep up with the latest data from TIGIT in the clinic with leaders from Merck, MD Anderson, UPMC and iTeos Therapeutics. Discuss and interpret emerging clinical data to advance biomarker strategy, novel indications, patient populations, and toxicity with clinical experts. 9:00 am Discussing the Strengths and Limitations of Pre-Clinical Data to Provide Rationale for .. continue reading Clinical Indication, Combination and Mechanism of Resistance. 9:30 am Bringing TIGIT Therapies into the Clinic Safely to Provide Proof of Concept for Pre-Clinical Evidence and Identify Rational Indications in vivo. 11:30 am Handling TIGIT in the Clinic, Building Clinical Trial Strategy, Managing Toxicity, and Optimizing Patient Selection to Maximize Clinical Trial Success. 12:00 pm Mastermind Session: Considering Evidence and Discussing the Potential for TIGIT in Expanded Indications and Handling TIGIT in the Clinic.


Starts at 07:45 AM GMT-4:00

Entry Fees

Check Official Website


upto 100
Estimated Count

Category & Type

Medical & Pharma


24 Sep 2020 Interested

Frequency Newly Listed

Official Links


Report Error
Claim this event


Logo Reserve a Slot

Hanson Wade Limited

UK 309 Total Events / 123 Upcoming Events 64+ Followers

More Events From The Organizer